Eating Disorders News and Research

Latest Eating Disorders News and Research

Gastrointestinal symptoms may interfere with nutritional management of ED patients

Eating disorders (ED) patients display a high prevalence of gastrointestinal symptoms and functional gastrointestinal disorders such as irritable bowel syndrome. These symptoms may interfere with their nutritional management. Ingestion of fructose-sorbitol (F-S) is an established means of gastrointestinal symptom provocation in irritable bowel syndrome patients.

20 Nov 2009

Interim data from an ongoing phase 1 dose-escalation trial of XL147 reported

Exelixis, Inc. today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors.

19 Nov 2009

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company’s second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.

18 Nov 2009

Interim data from Schering-Plough's narlaprevir Phase IIa study

Schering-Plough Corporation reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.

3 Nov 2009

Shire announces Phase IIIb study results of Daytrana

Shire plc, the global specialty biopharmaceutical company, today announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana® (methylphenidate transdermal system) in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).

31 Oct 2009

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Schering-Plough Corp. announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.

31 Oct 2009

School to college transition can trigger eating disorders in young adults

Research shows that the transition to college, with its inherent pressures and changes, can increase the likelihood of eating disorders in young adults. While college students are empowered with newfound independence, this freedom can also trigger unhealthy and dangerous behaviors.

27 Oct 2009

Rates of binge eating among adult women identical across race but not among college age women

Existing research shows that rates of binge eating among adult women is virtually identical across race. However, among college age women, it's a different story: Caucasian women are more apt to exhibit binge eating behaviors than African American women, according to a study presented at this month's annual scientific meeting of the Obesity Society.

26 Oct 2009

Study compares differences between inpatient and day treatment of bulimia nervosa

A German study published in the fifth issue of Psychotherapy and Psychosomatics compares the differences between inpatient and day treatment of bulimia nervosa.

23 Oct 2009

Shire announces new pharmacokinetic data of ADHD medication

Shire plc, the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder (ADHD) medication, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, which showed that Vyvanse provided similar concentrations of its active medication in the blood when administered either intranasally or when administered orally.

23 Oct 2009

Millennium commences Vc-R-CHOP Phase II trial for diffuse large B-cell lymphoma

Millennium: The Takeda Oncology Company today announced the initiation of a Phase II clinical trial examining rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with or without VELCADE® (bortezomib) for Injection for patients with a common type of lymphoma. The study will examine previously untreated patients with a genomically defined subtype of lymphoma called non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma.

22 Oct 2009

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.

19 Oct 2009

Soligenix commences enrollment in its Phase 3 Orbec clinical trial for acute GI GVHD

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated enrollment in its confirmatory Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial evaluating orBec(®) for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD).

15 Oct 2009

VitalProteinRx nutritional supplement for chronic kidney disease affected patients

VitalRemedyMD, a physician-established company, offers scientifically formulated integrative nutritional supplements designed to improve the quality of traditional healthcare. "We are proud that VitalProteinRx is now an integral part of Fresenius' armamentarium in helping patients with chronic kidney disease," stated Dr. Seth Baum, Founder of VitalRemedyMD.

13 Oct 2009

Cognitive behavioral therapy effective for bulimia and binge eating disorders

Although most people with bulimia and binge eating disorders wait many years before seeking help, a new review shows that psychological treatment can make a large difference — and that cognitive behavioral therapy (CBT) is the most effective talk therapy for these disorders.

6 Oct 2009

Eating Recovery Center expands inpatient facilites to meet increased demand

Answering increasing demand for specialized treatment of severe eating disorders, Eating Recovery Center (www.eatingrecoverycenter.com), a behavioral hospital focused on comprehensive and sustainable treatment of eating disorders, today announced that it will double its patient capacity, expanding its inpatient facilities from 12 beds to 24.

6 Oct 2009

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough Corp. announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for PEGINTRON® (pegylated interferon alfa-2b) in the adjuvant treatment of patients with Stage III malignant melanoma.

6 Oct 2009

2009 Mini-Psych School Program dispels myths surrounding mental illness

The Mental Illness Awareness Week is coming up, from October 4 to 10. On this occasion, Joseph Rochford, Ph.D., Director of the Academic Affairs at the Douglas Mental Health University Institute, presents his top ten list of myths about mental illness.

29 Sep 2009

Behavioral hospital receives Champion in Health Care award

Eating Recovery Center (www.eatingrecoverycenter.com), the only behavioral hospital in Colorado focused on comprehensive and sustainable treatment of eating disorders, was honored as a "Champion in Health Care" by the Denver Business Journal at the newspaper's annual awards ceremony last night.

26 Sep 2009

Bayer's regorafenib showed 50% stabilization rate in RCC patients

Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC).

22 Sep 2009